noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

ImmuCell Corporation

2025 Form 10-K (proofs 0000811641 118730 ALL DOCS clean pn120)
ImmuCell Corporation

Corporate Presentation (Investor Relations April 2026 Final)
Peakequity Partners Management Co LLC

PeakEquity Partners Successfully Exits G5

Healthcare

Pappas Capital LLC

03/23/2016 | Press release | Archived content

Envisia Therapeutics Secures $16.5 Million In Additional Series A...

News | 03. 23. 2016

Envisia Therapeutics

RESEARCH TRIANGLE PARK, NC - March 23, 2016 - Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today announced a $16.5 million investment from existing investors to support the accelerated development of the Company's pipeline of innovative extended-release ocular therapies for the three leading causes of preventable vision loss and blindness.

Pappas Capital LLC published this content on March 23, 2016, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 10:00 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format